Kinases are key targets for drug discovery. In the field of screening in general and especially in the kinase area, because of considerations of efficiency and cost, radioactivity-based assays tend to be replaced by alternative, mostly fluorescencebased, assays. Today, the limiting factor is rarely the number of data points that can be obtained but rather the quality of the data, enzyme availability, and cost. In this article, the authors describe the development of an assay for a kinase screen based on the electrophoretic separation of fluorescent product and substrate using a Caliper-based nanofluidics environment in on-chip incubation mode. The authors present the results of screening a focused set of 32,000 compounds together with confirmation data obtained in a filtration assay. In addition, they have made a small-scale comparison between the on-chip and off-chip nanofluidics screening modes. In their hands, the screen in on-chip mode is characterized by high precision most likely due to the absence of liquid pipetting; an excellent confirmation rate (62%) in an independent assay format, namely, filtration; and good sensitivity. This study led to the identification of 4 novel chemical series of inhibitors. (Journal of Biomolecular Screening 2006:359-368) 
INTRODUCTION
K INASES ARE A CLASS OF ENZYMES catalyzing the transfer of a phosphate group from adenosine triphosphate (ATP) to specific hydroxy residues of a substrate protein. They have been implicated as key players in numerous signal transduction pathways, stretching from the plasma membrane to the nucleus, and therefore represent a major drug target for the pharmaceutical industry in various disease areas. [1] [2] [3] Notably, 76 kinase inhibitors are reported to be at various stages of clinical development. 4 Moreover, the interest in this field has been further boosted by the commercial success of Glivec/Gleevec, a BCR/ABL and Kit kinase inhibitor launched for chronic myelogenous leukemia and gastrointestinal stromal cell tumors. 5 One prominent expert of kinases even dubbed them as "the major drug targets of the XXIst century." 6 Therefore, kinases are the focus of intense industrial research, alongside G protein-coupled receptors, proteases, and phosphatases, and this is reflected by the number of dedicated conferences and by the number of publications originating from the industry on this topic.
Numerous technologies have been developed for assessing kinase activity. Some of them necessitate the use of radiolabeled ATP and rely on scintillation proximity, either plate or bead based. 7 Alternative technologies are radioactivity free and based, for instance, on luminescence, as for measurement of ATP consumption with luciferase 8 or amplified luminescent proximity homogeneity assay (AlphaScreen). 9 Other technologies rely on fluorescence, such as fluorescence polarization, [10] [11] [12] [13] [14] timeresolved fluorescence resonance energy transfer/homogeneous time resolved fluorescence, 15, 16 fluorescence quenching, or measurement of fluorescence intensity after electrophoretic separation of substrate and product. 8, 17 Moreover, alternative assays based on binding have been developed, notably, competition of kinase binding to a broad-spectrum inhibitor or an ATP mimetic (e.g., DiscoverX, Fremont, CA). 18 One variation on this approach is to couple it to a display of the kinases on phages (Ambit, San Diego, CA). 19 In deciding on the most appropriate assay, an important parameter to consider is the desired throughput. In terms of screening paradigms at Serono, we do not consider ultra highthroughput screening (uHTS) and instead are following a more focused screening approach, notably for known target classes such as kinases. To this end, original methods for the selection of focused sets have been developed 20 and empirically validated through screening. Thus, for screening a focused set of 32,000 Molecular Screening and Cellular Pharmacology Department, Serono Pharmaceutical Research Institute, Geneva, Switzerland. compounds against a serine/threonine (Ser/Thr) kinase enzyme, nanofluidics technology from Caliper based on electrophoretic separation of substrate and product has been chosen and is described below. This technology will be referred to as "mobility shift assay" in the rest of this article.
MATERIALS AND METHODS

Materials
Unless otherwise stated, chemicals were purchased from Sigma-Fluka (Saint-Louis, MO 
Filtration assay
In a 96-well plate, 10 µl of compound at 50 µM in 25% DMSO or vehicle was incubated with 20 µl of enzyme (50 nM) and 20 µl of a mixture of ATP (100 µM), peptide (25 µM), and [ 33 P]-ATP (500 nCi/well). These reagents were diluted in a 20 mM HEPES pH 7.4 buffer containing 10 mM MgCl 2 , 0.01% Brij-35, and 1 mM dithiothreitol (DTT). The incubation at room temperature was stopped after 1 h by the addition of 50 µl 10 mM ethylene diamine tetraacetic acid (EDTA); 1 mM ATP and 80 µl of the assay volume were transferred onto a 96-well Unifilter P-81 cellulose phosphate paper filter plate (Whatman Inc., Clifton, NJ), filtered on a Multiscreen Vacuum Manifold (Millipore Corp., Billerica, MA), washed extensively with wash buffer containing 50% EtOH/49% H 2 O/1% orthophosphoric acid. Fifty microliters of scintillation cocktail was then added, and after 2 h of incubation, plates were counted in a Trilux scintillation counter (Wallac/Perkin-Elmer Life Sciences). Low controls (no compound, no enzyme present) and high controls (no compound, in the presence of enzyme) were in columns 1 and 12 of the plates. Signal-to-background (S/B) ratios were calculated by the following equations: S/B = mean signal/mean background, with signal being the high control and background being the low control value.
Mobility shift assay
The assay was run on a Caliper 250 Drug Discovery System (Caliper Life Sciences, Mountain View, CA) in buffer A (HEPES 100mM, MgCl 2 10mM, Brij-35 0.01%, pH 7.4) containing 5% DMSO.
On-chip mode of assay
In 384-well plates, 4 µl of compounds at 1 mM in DMSO were diluted immediately before use with 76 µl of 1.05X buffer A. Therefore, the compound concentration in the well was 50 µM in 5% DMSO, giving a final concentration of 12.5 µM in 5% DMSO in the reaction channel of the chip after sipping. Four sippers chips model FS433 were used, and instrument settings were the following: pressure applied: -1.5 psi, voltage applied: -1100∆V, sample sip time: 1 s. The 2 substrate reservoirs on the chip were each filled with 50 µl of a mixture of 20 µM of fluorescent peptide substrate and 500 µM ATP in buffer A, corresponding to a final concentration of 2 µM peptide and 50 µM ATP in reaction channel, whereas the 2 enzyme reservoirs were each filled with 50 µl of 3.4 µM of enzyme in kinase buffer 1X containing 1 mM DTT, corresponding to a final concentration of 690 nM in reaction channels. The enzyme reaction time was 1 min. As a low control (100% inhibition), H9 in an external reservoir was used at a concentration of 250 µM, corresponding to a final concentration of 62.5 µM in reaction channel. Compounds to be tested or vehicle were sipped from 384-well plates for 1 s. It should be noted that for assay development, concentrations of peptide, enzyme, ATP, and inhibitor varied depending on the parameter studied.
Determination of percentage of inhibition
In on-chip mode, the presence of an inhibitor was characterized by a decrease in the amount of product continuously formed in the reaction channel, and this translated into a dip in fluorescence intensity from the baseline (high control) on electrophoretic separation. The extent of the dip (d) was measured using HTS Well Analyzer Software, and the percentage of inhibition was calculated relative to a low control corresponding to 100% inhibition (250 µM of H9 sipped from a reservoir after the last well of the plate) according to the formula % inhibition = 100 × (1-(r-r low control )/ (r high control -r low control )). As a 50% inhibition control, H9 at a concentration of 40 µM corresponding to 10 µM in reaction channel was added in the 384-well plates in columns 2 and 23 to evaluate the quality of the screen.
Off-chip mode of assay
Compounds from a 1 mM stock in DMSO were diluted immediately before usage in buffer A 1.05X to get 5 µl at a concentration of 40 µM in 5% DMSO (final concentration in the assay: 10 µM in 5% DMSO). Five microliters of a mixture of peptide at 8 µM and ATP at 2 mM in buffer A containing 5% DMSO was added to the reaction well, corresponding to a final concentration in the assay of 2 µM peptide and 500 µM of ATP, whereas 10 µl of enzyme at 27.4 nM in the same buffer was added to start the reaction, corresponding to a final concentration of 13.7 nM in the assay. After 1 h of incubation, 20 µl of termination buffer (100 mM HEPES, pH 7.5, 0.15% Brij-35, 32 mM EDTA, DMSO 5%) containing 0.2% Caliper's coating reagent 3 was added, followed by 35 µl of trough buffer (half reaction buffer + half termination buffer) to complete the volume to 75 µl, the minimal volume required for sipping. The reaction mixture was sampled for 1 s by the TC372 12 sipper chip for electrophoretic separation of substrate and product peaks using the HTS 250 instrument under a pressure of -1.5 psi and a voltage of -2400∆V. It should be noted that for assay development, concentrations of peptide, enzyme, ATP, and inhibitor, as well as incubation time, varied depending on the parameter studied.
Determination of percentage of inhibition
In off-chip mode, the relative peak heights of substrate and product were measured and ratioed using HTS Well Analyzer Software from the manufacturer. The ratio (r) was defined as the heights of the product peak divided by the sum of the peak heights of product and substrate. The low controls corresponded to 100% inhibition in the presence of staurosporine 2 µM final dispensed in columns 1 and 24 and the high controls to the absence of compounds in columns 2 and 23. Percentage inhibition was calculated relative to high and low controls as % inhibition = 100 × (1-(r-r low control )/(r high control -r low control ).
Assay performance
To evaluate the quality of the assay for use in an HTS campaign, performance was assessed by calculating either a Z′ or a Z′ 50 factor value. The Z′ factor value was calculated using the following equation: Z′ = 1 -((3SD of high control) + (3SD of low control)) /⏐(mean of high control -mean of low control)⏐. 21 For the on-chip mode of assay, the low control (100% inhibition) could not be used for the calculation as it was sipped from a separate trough only once after each plate. Therefore, calculation of a Z′ 50 value was based on the high controls and 50% inhibition controls present in the screening plates as a substitute to the low controls.
Data analysis and visualization
All K m and IC 50 values were calculated using Prism software (Graphpad Software Inc., San Diego, CA). Data were visualized using Spotfire Decision Site 7.1 software (Spotfire, Goeteborg, Sweden).
RESULTS AND DISCUSSION
Characterization of the enzyme and feasibility of the mobility shift assay
The kinase to be screened against has been characterized in terms of kinetic properties in a classic filtration assay under strict Michaelis-Menten conditions (data not shown). Michaelis constant (K m ) values for ATP and substrate were determined to be 42.3 ± 2.0 µM and 4.8 ± 1.4 µM ( Table 1) , respectively. Specific activity of the kinase was calculated to be 30 nmol/ min/mg enzyme, and its k cat value was 1.5 min -1 (data not shown).
Mobility shift assays using the Caliper 250 station can be performed in 2 different modes, on chip and off chip. In on-chip mode, enzyme and substrate are sipped from reservoirs on the chip, whereas compounds are sipped from 384well plates, and the reaction takes place in a nanochannel on the chip in 1 min in a 1-to 2-nl volume, followed by an electrophoresis separation step and detection. In off-chip mode, the reaction takes place classically in a microplate well, is stopped, and a sample is sipped on the chip that is used only for separation and detection. Parameters of percentage of substrate conversion and apparent K m can be determined both in on-chip and off-chip modes. We use the term apparent K m values as the assays were not run under strict Michaelis-Menten conditions (nonlimiting substrate, negligible enzyme concentration, working at the initial velocity of the enzyme, low substrate conversion). In both on-chip and off-chip modes we were working at a high substrate conversion rate of 40% to be able to detect product formation. Moreover, in on-chip mode, the labeled fluorescent peptide concentration was limiting, and the enzyme concentration was nonnegligible compared to the substrate.
Preliminary experiments in the off-chip mode using the Caliper 250 station demonstrated the feasibility of the mobility shift approach because a conversion rate of 40% of the substrate was obtained within 40 min with 20 nM of enzyme. This level of conversion rate of the substrate is required to get sufficient product for reliable detection in screening mode. In the off-chip mode, apparent K m values for substrate and ATP were determined to be 8.8 µM ( Fig. 1) and 500 µM ( Fig. 2, Table 1 ), respectively. In the on-chip mode, the apparent K m value for ATP was found to be 25 µM (Fig. 2, Table 1) ; however, the equivalent value has not been determined for the peptide substrate because the maximal concentration that could be used in the assay was too low to reach a plateau. It should be noted that in the on-chip mode, an enzyme concentration of 690 nM was needed to get a substrate conversion rate of 40% in 1 min, whereas in off-chip mode, an enzyme concentration of 20 nM was sufficient to get the same level of conversion in 40 min. Therefore, to save enzyme, it was decided to run the off-chip assay for 60 min in the presence of 13.7 nM enzyme.
In the absence of known inhibitors of the studied kinase, the relative potency of the promiscuous inhibitor staurosporine was evaluated in the off-and on-chip modes. It displayed IC 50 values of 50 and 330 nM in the off-and on-chip modes, respectively ( Fig. 3, Table 1 ), indicative of a difference in sensitivity of 6 to 7 times between the 2 approaches. This difference could be explained by the very different kinetics (1 min v. 60 min) and enzyme concentrations (13.7 nM v. 690 nM) and by the observed stickiness of staurosporine to the nanochannel walls that might lower its real concentration in the assay. Using the filtration assay, an IC 50 value of 75 nM was obtained (data not shown), very close to that obtained in the off-chip mode. This could be linked to the fact that the assay conditions were comparable in terms of enzyme concentration and kinetics, even if the ATP concentrations differed by a factor of 12 and if staurosporine is a competitive inhibitor toward ATP.
From these results, despite the somehow reduced sensitivity in on-chip mode, given the advantage of a significantly reduced enzyme consumption ( Table 1) , we decided to pursue the development of a screening assay in this mode. The enzyme consumption was calculated based on the 100 µl of enzyme (3.4 µM) that had to be distributed to a chip for a run of 12 plates even if only a few microliters were actually consumed.
Validation of the assay
Although percentage of inhibition was calculated relative to a low control corresponding to 100% inhibition sipped from a separate trough after each plate, using high concentrations of reference inhibitors on the 384-well plates in the on-chip mode is unsuitable for screening as it leads to a slow return to the baseline after each control well. Therefore, to evaluate the assay variability in on-chip mode and to determine a reasonable cutoff to select positives, the frequency distribution of the 50% inhibition controls, that is, values obtained in the presence of 10 µM H9 and high controls, was studied ( Fig. 4) . Values obtained for the high control (i.e., in the absence of test compounds) were tight, with an average of 2.2% inhibition with a standard deviation (SD) of 1.7. Similarly, for the 50% controls, corresponding to approximately 50% inhibition in a dose-response experiment, values were also tight with an average of 62.4% inhibition with an SD of 5.2. H9 was chosen as a control for on-chip assays as staurosporine was found to stick to the nanochannels of the chips, slowing the return to baseline level in screening mode. Moreover, other experiments in on-chip mode demonstrated that the enzyme could be left on the chip for up to 10 h without a drop in activity (data not shown). Therefore, we can conclude that the buffering capacity of our solutions is adequate for the duration of a screening run. Finally, the enzyme activity was found to be insensitive to DMSO at concentrations up to 10% (data not shown). Therefore, to maximize compounds' solubility, screening was performed in the presence of 5% DMSO.
Screening in on-chip mode
A selected focused set of 32,000 compounds from our collection has been assembled in a 384-well plated format to be assessed singly on the Caliper 250 in an on-chip mode at a concentration of 12.5 µM. Runs of up to 12 plates were performed (run time = 10 h). Performance of the assay was good with a Z′ 50 value of 0.77. Calculation of the Z′ 50 value was based on the 50% inhibition controls and high controls present in the screening plates as described in the "Validation" section. The low control (100% inhibition) could not be used for the calculation as it was sipped from a separate trough only once after each plate.
The most impressive characteristic of the mobility shift assay technology was the very low background obtained in the absence of compounds with an average of 2.2% inhibition and an SD of 1.7% (Fig. 4) . This translated into a cutoff of 9% at 3 times the SD. We chose to be even more stringent, using a cutoff value of 11% for selecting positives. A total of 257 positives corresponding to these criteria have been obtained, corresponding to a hit rate of 0.8%.
For confirmation, all 257 positives from the on-chip assay were retested in a different format, namely, a 33 P-ATP filtration assay at a concentration of 10 µM. In the validation of the filtration assay on one 96-well plate containing 5% DMSO in each well, the value of the mean high control was found to vary in function of its position in the plate, 0 ± 10.5% inhibition in column 1 and 7.0 ± 8.7% in columns 2 through 11, respectively (Fig. 5) . The discrepancy between these values is most probably due to an edge effect observed at several occasions in the manual filtration format. As the filtration assays were inherently noisier than the electrophoretic separation assay was, we considered a compound to be positive in the filtration assay when it inhibited the enzyme by at least 24% (i.e., mean high control value +2 SD) in duplicate. 
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FIG. 4. Dispersion of the control values of the on-chip kinase assay.
The variability of the assay has been evaluated using 9 plates from Using these criteria, 160 of 257 compounds (62%) retested positive, although there was no good correlation between the percentages of inhibition obtained with the 2 methods (data not shown). This could be due to the very different assay conditions used in both assays (see Table 1 ) in terms of duration of the reaction and concentration of enzyme and substrate. Such discrepancies have been reported previously comparing on-and off-chip mobility shift assays. 22 In these latter experiments, too, enzyme concentration in on-chip mode was 70 to 200 times higher than in the off-chip mode, and reaction times were 1 versus 30 min, whereas ATP concentrations were identical. The observed differences in compound potency were linked to the potential stickiness to the channel walls of some compounds or their slow binding behavior. It is probable that the same factors are influencing our results. From these confirmed positives, 30 were selected, and IC 50 values were determined in filtration format. Eleven of the selected compounds displayed an IC 50 value less than 3 µM (data not shown), whereas the others were between 3 and 10 µM.
To evaluate how many compounds we might be missing (i.e., the false-negative rate), we performed a filtration assay using 8 randomly chosen whole 96-well plates in which no positives had been detected in the on-chip mode. This corresponded to a total of 605 compounds. Only 8 compounds displayed a percentage of inhibition greater than the 24% threshold (Fig. 6A) . These compounds were retested in full dose response using the filtration assay method starting at a concentration of 20 µM, and none appeared to be a potent inhibitor (Fig. 6B) . Therefore, from this limited sample of compounds, we conclude that the mobility shift assay technology is at least as sensitive as a classic radioactivity-based filtration assay and that the false-negative rate is low, in this case, 8 weak positives of 605 compounds tested.
To assess further the robustness of the on-chip mobility shift assay, 10,681 compounds were retested to obtain duplicate values. Most of these compounds were inactive on both occasions and were not analyzed further (gray spots in Fig. 7) . Of the 66 compounds that scored positive on at least 1 occasion, surprisingly only 3 were positive in duplicate. Nevertheless, all 66 compounds were retested in the filtration assay, and 49 were confirmed positive (blue spots in Fig. 7) . This included 15 of the 16 positives in run 1 only and 31 of the 47 positives in run 2 only. The 3 compounds that were positive in both assays were also confirmed positive in the filtration assay. Interestingly, of the 16 compounds from run 2, which were retested in filtration and not confirmed positive, 13 displayed an inhibition level less than 15% in the on-chip assay, suggesting that they are only weak inhibitors at best. Therefore, our initial threshold of 11% inhibition (corresponding to 5 SD from blank value) in the on-chip mode may not have been sufficiently stringent. However, elevating only slightly this threshold to 15% inhibition (7 SD from the blank) might have been enough to eliminate most false positives (Fig. 7) . It is worth noting that these values are comparable to the cutoff value of 13.7% inhibition previously reported for a mobility shift assay. 8 In view of the surprising discrepancy between duplicates in which only 3 compounds were positive in both runs, we decided to analyze the screening data in more detail for the 46 nonduplicated positives, which showed activity in the filtration assay. This analysis showed that of these, 28 were weak positives in the on-chip assay (<15% inhibition at most); 4 could be traced to the fact that following a machine upgrade, a different software-namely, HTS Well Analyzer 4.1 instead of 4.0-was used between n1 and n2, allowing for a greater sensitivity during the 2nd run; and 22 could be related to sipper problems generating a high background. It should be noted that some compounds were both weak positives and linked to sipper problems. The remaining 7 compounds were not scored as weak positives in the on-chip assay (>15% inhibition) and were confirmed as positives in the filtration assay. For these compounds, we have no obvious explanation for the discrepancy between run 1 and run 2. The critical factor that emerged as a result of these experiments was the question of the chip quality. We noted that when chip quality degraded, the background of the blank (absence of inhibitor) increased to more than 10% with an SD of up to 7 instead of 1 to 2 in normal conditions. Our current practice is therefore to discard results obtained when the SD of the controls increases to greater than 3%. From a strictly pragmatic point of view, duplicate screening would probably be warranted only if the hit rate were very low or if no interesting compound emerged from the 1st screen.
Comparison of on-chip versus off-chip
The assay conditions for on-and off-chip assay methods have major differences ( Table 1) . Most notably, in the on-chip assay, the ATP concentration is 25 as compared to 500 µM in the off-chip assay, the enzyme concentration is 690 nM as compared to 13.7 nM, and maybe even more important, the reaction time is 1 min as compared to 60 min. To address the question of the impact of these differences on the relative sensitivities of the on-and off-chip modes, 1628 compounds, corresponding to twenty-four 96-well plates, which had already been screened in the on-chip mode and displayed most of the positives, were retested in the off-chip mode at a concentration of 10 µM.
The 1st step was to assess that both buffering capacity of our assay solutions and product stability were adequate throughout the run, as this is one of the critical factors limiting the duration of operation. In the off-chip mode, a dose-response curve of staurosporine was performed, the assay was stopped, and the wells were sampled every 1.5 h over a period of 7.5 h. No change in the IC 50 value was observed for up to 7.5 h, with values obtained in this experiment ranging from 35 to 37 nM (data not shown), very close to those described in the "Feasibility" section. Therefore, we can conclude that the reaction product is stable and that the buffering capacity of our solutions is adequate. The quality of the screening data was good, although less reproducible than the on-chip data, with a Z′ factor value of 0.52 instead of a Z′ 50 value of 0.77. This is most probably because of the absence of liquid pipetting in the on-chip mode, which removes an important source of variation. The mean of the blanks (in the absence of inhibitor) was 0.31% inhibition with an SD of 6.3% (Fig. 8) . This SD value compares with the value of 1.7% obtained in the on-chip mode. Taking as a cutoff for positives the value of the blank plus 3 SD, we obtain a threshold of 19.3% for the selection of positives. Applying this threshold of 19% inhibition, 86 positives were detected in the off-chip mode. This is to be compared with the 79 positives that had been detected previously in the on-chip mode. However, only 6 common positives were detected by both methods, and all 6 were confirmed positive in the filtration assay ( Fig. 9) . Of the other 73 positives in the on-chip assay, 43 were confirmed in a radioactivity-based format, whereas of the other 80 positives in the off-chip mode, 30 were confirmed as positives (data not shown). The limited sample, however, does not allow us to conclude whether the difference in confirmation is significantly different for both methods.
Counterintuitively, the on-chip mode seems to be more sensitive than the off-chip mode, even if higher enzyme concentrations are used. This result might be linked to the very low standard deviation observed in the on-chip mode, probably due to the absence of liquid handling.
CONCLUSION
The feasibility of on-chip screening using the Caliper 250 station has been demonstrated under real-life screening conditions. On-chip screening offers 2 major advantages, notably, reduced reagent costs, and in particular lower enzyme consumption, and independence from distribution steps and therefore from systematic or random errors linked to liquid transfer. This latter point is reflected by the very low SD of the results. Moreover, the high quality of the data enabled us to screen in single instead of in duplicate points, which is a further factor leading to cost reduction.
The screening campaign described here has allowed us to detect a number of positive compounds belonging to 4 chemical classes, some of which displayed IC 50 values in the low micromolar range. Another impressive characteristic of the mobility shift assay is the high confirmation rate obtained in a different, radioactivity-based format, namely, filtration, with a 62% confirmation rate. This result compares very favorably with those obtained when assessing compounds in both fluorescence-based and filtration assays either in the literature 23 or in house, where the confirmation rates of 17% and 38%, respectively, were obtained when comparing fluorescence polarization or homogeneous time resolved fluorescence to filtration (D. Perrin et al., unpublished data). Interestingly, however, when comparing the on-and off-chip screening modes, some positive compounds detected in one mode were not detected in the other. However, it is not possible to conclude whether one method is superior to the other. It should be pointed out that these results are in contrast to results obtained at Caliper Life Sciences with known kinase inhibitors in which the correlation between the on-chip and off-chip modes was reasonable even if generally, compounds were found to be less potent in the on-chip mode. 22 In this latter publication, the concentrations of the 4 enzymes used were 70 to 200 times higher in the on-chip than in the off-chip mode, similar to the conditions we used in this study. Moreover, the on-chip mode was found to be less sensitive than the off-chip mode, especially for precipitating, aggregating, and slow-binding compounds. Interestingly, the authors propose that working at high enzyme concentrations might diminish the interference by promiscuous, aggregating compounds. However, the results presented here may reflect more closely a real-life screening situation with a diverse though focused library of compounds with unknown properties as compared to a selected subset of known kinase inhibitors. Slow-binding behavior or stickiness of compounds might explain why some inhibitors are not detected in the on-chip mode. On the other hand, the high ATP concentration (namely, 500 µM) that had to be used in the off-chip mode to achieve a high enough conversion rate might have been detrimental to the detection of ATP-competitive inhibitors with low K i values that would have been detected in the on-chip mode. Therefore, one potential approach to maximize the number of positives could be to perform the screen in single in both modes. One critical aspect of the mobility shift assay, which became apparent during the course of these experiments, is the quality of the chip. Retrospectively, careful analysis of the results revealed that most of the false positives as well as missed positives (false negatives) were linked to the quality of the sipper or the age of the chip. Moreover, during development, we found that the mobility shift assay was very sensitive to the aging of buffers; therefore, for the screens in both the on-and off-chip modes, compounds and controls were diluted immediately before use.
How universally applicable is this technology? One general limitation is the number of compounds that can be tested in a given experiment. In our case, in which the screening philosophy is to evaluate focused sets of compounds, this limitation is of less consequence, and the throughput of a nanofluidicsbased mobility shift assay is quite adequate to meet the needs of such an approach. A 2nd limitation is the need for a peptide substrate. This imposes constraints on overall size and charge and means that generic proteins such as casein or myelin basic protein cannot be used. A 3rd limitation is that in the on-chip mode, the enzyme is required to work at a substrate conversion rate of 40% in 1 min, which is far from Michaelis-Menten conditions. Moreover, high enzyme concentration and short time of contact with the inhibitor might affect sensitivity of the assay. Finally, the enzyme must have a high catalytic activity to reach 40% conversion in 1 min, which in practice means that not all enzymes are amenable to this type of screening.
In the off-chip mode, the reaction takes place in standard microplate wells, and the Caliper HTS 250 is used simply as a reader. In both modes, a major advantage of this technology is that the separation of product and substrate gives a high precision with limited interference between fluorescent compounds. In future improvements of the mobility shift technology, one could envisage achieving increased throughput through monitoring more channels in parallel on 1 chip or being able to work at a lower enzyme conversion rate, heating the chip at 37° C to increase the reaction speed and lengthening the reaction channel to increase reaction time on the chip.
